

Advancements in Cellular Therapy for Autoimmune Diseases and Chronic Haematological Malignancies

Preliminary Programme

Rome, Italy 18-20 September 2025

Thursday, 18 September 2025

10:00 – 12:00	Scientific Business Meetings	
13:00 - 13:55	Session I: Current EBMT recommendations	
13:00 – 13:15	Chairs: Tobias Alexander (DE) & Donal McLornan (UK) EBMT recommendations for HCT in MDS	Carmelo Gurnari (IT)
13:15 – 13:30	EBMT recommendations for HCT in autoimmune diseases	Elisa Roldan Galvan (UK)
13:30 – 13:45	EBMT recommendations for CART in autoimmune diseases	Raffaella Greco (IT)
13:45 – 13:55	Panel discussion	National Greek (11)
13:55 – 15:00	Session II: MDS diagnosis and prognosis	
	Chairs: Kavita Raj (UK) & Adriano Venditti (IT)	
13:55 – 14:10	MDS in 2025: a molecular era of diagnostic and prognostic classifiers	Mario Cazzola (IT)
14:10 – 14:25	HCT or not in MDS? How to decide with current prognostic scoring systems	Nico Gagelmann (DE)
14:25 – 14:40	Are we ready for AI to help in the management of MDS?	Adrian Mosquera (ES)
14:40 – 15:00	Panel discussion	
15:00 - 15:30	Coffee break	
15:30 - 16:50	Session III: MDS treatment	
45.00 45.45	Chairs: Fernando Barroso Duarte (BR) & Nicolaus Kröger (DE)	
15:30 – 15:45	Current treatment algorithm in Lower-risk MDS	Maria Teresa Voso (IT)
15:45 – 16:00	Current treatment algorithm in Higher-risk MDS and the AML/MDS border	Amer Zeidan (US)
16:00 – 16:15	Therapeutic vulnerability in MDS/AML: looking into the future from the lab standpoint	Jaraslaw Maninipuski (LIC)
16:15 – 16:30	Access to genomics and transplant policies in MDS in Latin-America	Jaroslaw Maciejewski (US) Gonzalo Bentolila (AR)
16:30 – 16:40	Case presentation	Giuliano Filippini Velazquez (DE)
16:40 – 16:50	Panel discussion	Oldilario i ilippirii velazquez (DL)
16:50 – 17:20	Coffee break	
17:20 – 18:25	Session IV: Autoinflammation in haematology and beyond	
	Chairs: Joanna Drozd-Sokolowska (PL) & Anna Paola Iori (IT)	
17:20 - 17:35	VEXAS: the lynchpin between inflammation and myeloid neoplasia	Carmelo Gurnari (IT)
17:35 – 17:50	CMML and autoimmune/inflammatory conditions	Francesco Onida (IT)
17:50 - 18:05	or in the distribution of initial or in the distribution of the di	
17.50 - 10.05	Incidence and management of HLH in autoimmune diseases	Coralie Bloch (FR)
18:05 – 18:15		• •



09:00 - 10:10

Advancements in Cellular Therapy for Autoimmune Diseases and Chronic Haematological Malignancies

Preliminary Programme

Joint Physician-Nurse session HCT in MDS in 2025

Rome, Italy 18-20 September 2025

Friday, 19 September 2025

09:00 - 10:10 09:00 - 09:15 09:15 - 09:30 09:30 - 09:45 09:45 - 10:00 10:00 - 10:15	Chairs: Maaike de Ruijter (NL) & William Arcese (IT) Which donor to choose in the PtCy era? Bridging or not prior to allo-HCT for MDS? Conditioning regimens in the contemporary era Issues on maintenance and management of relapse Panel discussion	Kavita Raj (UK) Nicolaus Kröger (DE) Joanna Drozd-Sokolowska (PL) Marie Robin (FR)
10:15 – 11:00	Industry Symposium	
11:00 – 11:30	Coffee break	
11:30 – 12:50	Session V: HCT in autoinflammation and autoimmunity Chairs: John Snowden (UK) & Andrea Bacigalupo (IT)	
11:30 – 11:45	HCT in VEXAS	Donal McLornan (UK)
11:45 – 12:00	HCT in Behçet's disease	Mathieu Puyade (FR)
12:00 - 12:15	HCT in systemic sclerosis	Nicoletta del Papa (IT)
12:15 - 12:30	HCT for AID in Brazil: Current Practices	Fernando Barroso Duarte (BR)
12:30 – 12:40	Case presentation	Gavin Brittain (UK)
12:40 – 12:50	Panel discussion	
12:50 – 14:00	Lunch break	
14:00 – 15:20	00 – 15:20 Session VI: Plasma cells as treatment targets in haematology and autoimmune diseases	
	Chairs: Patrizia Chiusolo (IT) & Paolo Muraro (UK)	
14:00 – 14:15	Novel treatment approaches in myeloma	Elisa Roldan Galvan (UK)
14:15 – 14:30	Bispecifics in myeloma: bridging to CAR-T?	Patrick Hayden (IE)
14:30 – 14:45	Bone marrow plasma cell landscape in health and disease	Farzin Mashreghi (DE)
14:45 – 15:00	Plasma cell depletion in autoimmune diseases	Tobias Alexander (DE)
15:00 – 15:10	Case presentation	Paulina Piesik (CA)
15:10 – 15:20	Case presentation	Jonathan Wickel (DE)
15:20 - 15:50	Coffee break	
15:50 – 17:15	Session VII: Novel cellular therapies in autoimmune diseases Chairs: Simona Sica (IT) & Dominique Farge (FR)	
15:50 - 16:05	Bispecific antibodies in rheumatoid arthritis	Ricardo Grieshaber (DE)
16:05 – 16:20	CART in rheumatoid arthritis	Doron Rimar (IS)
16:20 – 16:35	CAR-T cell therapies in pediatric autoimmune diseases	Marco Becilli (IT)
16:35 – 16:50	iPS cells for tissue regeneration in autoimmune disease	Richard Burt (US)
16:50 – 17:00	Case presentation	Ioanna Minopoulou (DE)
17:00 – 17:15	Panel discussion	



08:45 - 09:45

08:45 - 09:00

Advancements in Cellular Therapy for Autoimmune Diseases and Chronic Haematological Malignancies

Preliminary Programme

Autologous HCT in MS

Chairs: Claudia Boglione (IT) & Basil Sharrack (UK)

Rome, Italy 18-20 September 2025

Saturday, 20 September 2025

Alice Mariottini (IT)

	09:00 - 09:15 09:15 - 09:30 09:30 - 09:45	CAR T in MS Cellular therapies in other neurologic indications Panel discussion	Lena Kristina Pfeffer (DE) Aiden Haghikia (DE)
	10:00 – 10:45	Industry Symposium	
	10:45 – 11:30	Poster Tour Chairs: Tobias Alexander (DE) & Donal McLornan (UK)	
	Poster 1	What essential information should be included in a patient information leaflet to effectively guide individuals with Multiple Sclerosis (MS) who are considering	
	Poster 2	or undergoing autologous hematopoietic stem cell transplantation (aHSCT)? Anti-ROR1 CAR T cells enhanced with safety iCasp9 suicidal gene expression as	Hannah Young (UK)
		novel immunotherapy for mantle cell lymphoma	Madalina Nistor (RO)
	Poster 3	Role of cardiovascular risk stratification in patients undergoing autologous stem cell transplantation for multiple myeloma: a real-life, single-centre evaluation	Ambra Fumagalli (IT)
	Poster 4	To be announced	Giorgia Ranucci (IT)
	Poster 5	Aggressive Systemic Mastocytosis Associated With	3 ()
		High Risk Myelodysplastic Syndrome	Lugain Abdalla (UK)
11:30 – 12:45 Session VIII: Immune monitoring post CART and late complications for autoimmune dise			mmune disease
		Chairs: Franco Locatelli (IT) & Raffaella Greco (IT)	
	11:30 – 11:45	Immune monitoring post-CART	Simona Pagliuca (FR)
	11:45 – 12:00	Late complications in HCT	Kirill Krigizov (RU)
	12:00 – 12:15	Late complications in CART	Maeve O'Reilly (UK)
	12:15 – 12:30 12:30 – 12:45	Secondary HLH after CART Panel discussion	Matteo Doglio (IT)
	12:45 – 13:00	Take home massages from all the organizers	
	12.40 - 13.00	Take-home messages from all the organizers	

Joint Nurse-Physician session HSCT and cellular therapies for autoimmune neurologic diseases